Cargando…

Temozolomide and Lomustine Induce Tissue Factor Expression and Procoagulant Activity in Glioblastoma Cells In Vitro

SIMPLE SUMMARY: Cancer patients, particularly with glioblastoma (GBM), are at increased risk for thrombosis. This risk is further increased upon treatment with chemotherapy. Tissue factor (TF) is the initiator of the extrinsic coagulation pathway and expressed by GBM cells. Chemotherapy is known to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kapteijn, Maaike Y., Zwaan, Shanna, ter Linden, Esther, Laghmani, El Houari, van den Akker, Rob F. P., Rondon, Araci M. R., van der Zanden, Sabina Y., Neefjes, Jacques, Versteeg, Henri H., Buijs, Jeroen T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137012/ https://www.ncbi.nlm.nih.gov/pubmed/37190275 http://dx.doi.org/10.3390/cancers15082347

Ejemplares similares

Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro
por: Fuchs, Daniel, et al.
Publicado: (2023)

Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines
por: Fishman, Hila, et al.
Publicado: (2023)

ET-02 EFFICACY OF THE SALVAGE THERAPY VIA LOMUSTINE AND NIMUSTINE FOR RECURRENT GLIOBLASTOMA WITH TEMOZOLOMIDE RESISTANCE
por: Yamamuro, Shun, et al.
Publicado: (2019)

Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance
por: Yamamuro, Shun, et al.
Publicado: (2021)

Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial
por: Weller, J., et al.
Publicado: (2023)

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: Van Den Bent, Martin, et al.
Publicado: (2020)

A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma
por: Larkin, J M G, et al.
Publicado: (2007)

Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2020)

Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial
por: Patil, Vijay M., et al.
Publicado: (2022)

New insights into the activities and toxicities of the old anticancer drug doxorubicin
por: van der Zanden, Sabina Y., et al.
Publicado: (2020)

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
por: Capper, David, et al.
Publicado: (2017)

Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial
por: Tremont-Lukats, Ivo W., et al.
Publicado: (2019)

Evaluation of Proton-Induced DNA Damage in 3D-Engineered Glioblastoma Microenvironments
por: Akolawala, Qais, et al.
Publicado: (2022)

Tumor‐expressed microRNAs associated with venous thromboembolism in colorectal cancer
por: Anijs, Rayna J. S., et al.
Publicado: (2022)

Lung toxicity of lomustine in the treatment of progressive gliomas
por: Seliger, Corinna, et al.
Publicado: (2022)

De-Palmitoylation of Tissue Factor Regulates Its Activity, Phosphorylation and Cellular Functions
por: Ettelaie, Camille, et al.
Publicado: (2021)

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
por: Beije, N, et al.
Publicado: (2015)

The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice
por: Buijs, Jeroen T., et al.
Publicado: (2019)

Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis
por: Song, Jie, et al.
Publicado: (2018)

Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis
por: Ren, Xing, et al.
Publicado: (2021)

Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
por: Das, Sunit, et al.
Publicado: (2020)

Procoagulant activity and thrombelastography in Korean hemorrhagic fever.
por: Lee, M., et al.
Publicado: (1986)

Lomustine induced acute pulmonary toxicity in a pediatric medulloblastoma survivor
por: Radhakrishnan, Venkatraman, et al.
Publicado: (2017)

Lomustine, methotrexate and cytarabine chemotherapy as a rescue treatment for feline lymphoma
por: Smallwood, Katherine, et al.
Publicado: (2020)

Lowering Low-Density Lipoprotein Particles in Plasma Using Dextran Sulphate Co-Precipitates Procoagulant Extracellular Vesicles
por: Wang, Jiong-Wei, et al.
Publicado: (2017)

Lomustine’s nanoemulsion as nose-to-brain drug delivery system for CNS tumor treatment
por: Alaayedi, Maryam H., et al.
Publicado: (2023)

Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents
por: Wander, Dennis P. A., et al.
Publicado: (2020)

The procoagulant effects of fine particulate matter in vivo
por: Kilinç, Evren, et al.
Publicado: (2011)

Procoagulant Microparticles in Dogs with Immune‐Mediated Hemolytic Anemia
por: Kidd, L., et al.
Publicado: (2015)

Clinical significance of procoagulant microparticles
por: Nomura, Shosaku, et al.
Publicado: (2015)

Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas
por: Kim, Young-Joo, et al.
Publicado: (2015)

Carnosic acid impedes cell growth and enhances anticancer effects of carmustine and lomustine in melanoma
por: Lin, Kun-I, et al.
Publicado: (2018)

Alkylation and Carbamylation Effects of Lomustine and Its Major Metabolites and MGMT Expression in Canine Cells
por: Chakkath, Thushara, et al.
Publicado: (2015)

Toxicity Profile of Procarbazine Lomustine and Vincristine Chemotherapy in Low-Grade Glioma - Retrospective Review
por: Irfan, Nabia, et al.
Publicado: (2020)

Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma
por: Kaptein, Fleur H. J., et al.
Publicado: (2022)

Procoagulant factor levels and risk of venous thrombosis in the elderly
por: Wang, Huijie, et al.
Publicado: (2020)

Procoagulant Activity in Amniotic Fluid Is Associated with Fetal-Derived Extracellular Vesicles
por: Butov, Kirill R., et al.
Publicado: (2022)

Induction of Fatigue by Specific Anthracycline Cancer Drugs through Disruption of the Circadian Pacemaker
por: Wang, Yumeng, et al.
Publicado: (2022)

Plasma lipid profiling of different types of hepatic fibrosis induced by carbon tetrachloride and lomustine in rats
por: Ishikawa, Masaki, et al.
Publicado: (2016)

Pulse‐Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs
por: Burton, J.H., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ulep1d2bu1as78htdd1a1s29pq